You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

274 Results
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
Drug
Other Name(s): Akeega™
Dec 1969
Les fiches d’information sur les soins palliatifs pour les Autochtones sont élaborées afin de soutenir les membres des Premières Nations, des Inuits...
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma
Jan 2026
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Oct 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Jan 2026

Pages